BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Geller DS, Morris J, Revskaya E, Kahn M, Zhang W, Piperdi S, Park A, Koirala P, Guzik H, Hall C, Hoang B, Yang R, Roth M, Gill J, Gorlick R, Dadachova E. Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R). Nucl Med Biol 2016;43:812-7. [PMID: 27744117 DOI: 10.1016/j.nucmedbio.2016.07.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Chen Z, Guo J, Zhang K, Guo Y. TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data. Dis Markers 2016;2016:4639575. [PMID: 27239089 DOI: 10.1155/2016/4639575] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
2 Jiang F, Shi Y, Lu H, Li G. Armadillo Repeat-Containing Protein 8 (ARMC8) Silencing Inhibits Proliferation and Invasion in Osteosarcoma Cells. Oncol Res 2016;24:381-9. [PMID: 27712595 DOI: 10.3727/096504016X14685034103392] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
3 Zvi Y, Ugur E, Batko B, Gill J, Roth M, Gorlick R, Hall D, Tingling J, Barkauskas DA, Zhang J, Yang R, Hoang BH, Geller DS. Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma. Sarcoma 2021;2021:8324348. [PMID: 33603563 DOI: 10.1155/2021/8324348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Xu Z, He W, Ke T, Zhang Y, Zhang G. DHRS12 inhibits the proliferation and metastasis of osteosarcoma via Wnt3a/β-catenin pathway. Future Oncol 2020;16:665-74. [PMID: 32250163 DOI: 10.2217/fon-2019-0432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Zhou J, Xu L, Yang P, Lin S, Huang H. Circ-ATAD1 is overexpressed in osteosarcoma (OS) and suppresses the maturation of miR-154-5p to increase cell invasion and migration. J Orthop Surg Res 2021;16:699. [PMID: 34857012 DOI: 10.1186/s13018-021-02809-4] [Reference Citation Analysis]
6 Lepareur N, Lacœuille F, Bouvry C, Hindré F, Garcion E, Chérel M, Noiret N, Garin E, Knapp FFR Jr. Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives. Front Med (Lausanne) 2019;6:132. [PMID: 31259173 DOI: 10.3389/fmed.2019.00132] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 11.7] [Reference Citation Analysis]
7 Pereira-Silva M, Alvarez-Lorenzo C, Concheiro A, Santos AC, Veiga F, Figueiras A. Nanomedicine in osteosarcoma therapy: Micelleplexes for delivery of nucleic acids and drugs toward osteosarcoma-targeted therapies. Eur J Pharm Biopharm 2020;148:88-106. [PMID: 31958514 DOI: 10.1016/j.ejpb.2019.10.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
8 Katal S, Maldonado A, Carrascoso J, Assadi M, Gholamrezanezhad A. Theranostic Agents in Musculoskeletal Disorders. PET Clin 2021;16:441-8. [PMID: 34053587 DOI: 10.1016/j.cpet.2021.03.008] [Reference Citation Analysis]
9 Beltrán Hernández I, Kromhout JZ, Teske E, Hennink WE, van Nimwegen SA, Oliveira S. Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other? Theranostics 2021;11:3882-97. [PMID: 33664868 DOI: 10.7150/thno.55760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Mercatelli D, Bortolotti M, Bazzocchi A, Bolognesi A, Polito L. Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives. Biomedicines 2018;6:E19. [PMID: 29439419 DOI: 10.3390/biomedicines6010019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
11 Zhang Y, Zvi YS, Batko B, Zaphiros N, O'Donnell EF, Wang J, Sato K, Yang R, Geller DS, Koirala P, Zhang W, Du X, Piperdi S, Liu Y, Zheng D, Roth M, Gill J, Zhang J, Ren T, Gorlick R, Zi X, Hoang BH. Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma. Sci Rep 2018;8:14294. [PMID: 30250282 DOI: 10.1038/s41598-018-32428-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
12 Karkare S, Allen KJH, Jiao R, Malo ME, Dawicki W, Helal M, Godson DL, Dickinson R, MacDonald-Dickinson V, Yang R, Hoang B, Gorlick R, Geller DS, Dadachova E. Detection and targeting insulin growth factor receptor type 2 (IGF2R) in osteosarcoma PDX in mouse models and in canine osteosarcoma tumors. Sci Rep 2019;9:11476. [PMID: 31391495 DOI: 10.1038/s41598-019-47808-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Wang M, Cai X, Yang J, Wang C, Tong L, Xiao J, Li L. A Targeted and pH-Responsive Bortezomib Nanomedicine in the Treatment of Metastatic Bone Tumors. ACS Appl Mater Interfaces 2018;10:41003-11. [DOI: 10.1021/acsami.8b07527] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
14 Chen T, Chen Z, Lian X, Wu W, Chu L, Zhang S, Wang L. MUC 15 Promotes Osteosarcoma Cell Proliferation, Migration and Invasion through Livin, MMP-2/MMP-9 and Wnt/β-Catenin Signal Pathway. J Cancer 2021;12:467-73. [PMID: 33391443 DOI: 10.7150/jca.49641] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
15 Broqueza J, Prabaharan CB, Allen KJH, Jiao R, Fisher DR, Dickinson R, MacDonald-Dickinson V, Uppalapati M, Dadachova E. Radioimmunotherapy Targeting IGF2R on Canine-Patient-Derived Osteosarcoma Tumors in Mice and Radiation Dosimetry in Canine and Pediatric Models. Pharmaceuticals (Basel) 2021;15:10. [PMID: 35056067 DOI: 10.3390/ph15010010] [Reference Citation Analysis]
16 Broqueza J, Prabaharan CB, Andrahennadi S, Allen KJH, Dickinson R, MacDonald-Dickinson V, Dadachova E, Uppalapati M. Novel Human Antibodies to Insulin Growth Factor 2 Receptor (IGF2R) for Radioimmunoimaging and Therapy of Canine and Human Osteosarcoma. Cancers (Basel) 2021;13:2208. [PMID: 34064450 DOI: 10.3390/cancers13092208] [Reference Citation Analysis]